Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,004 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Author Correction: Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy.
Gharbi SI, Pelletier LA, Espada A, Gutiérrez J, Sanfeliciano SMG, Rauch CT, Ganado MP, Baquero C, Zapatero E, Zhang A, Benach J, Russell AM, Cano L, Gomez S, Broughton H, Pulliam N, Perez CM, Torres R, Debets MF, de Dios A, Puig O, Hilgers MT, Lallena MJ. Gharbi SI, et al. Among authors: torres r. NPJ Breast Cancer. 2022 Dec 28;8(1):133. doi: 10.1038/s41523-022-00503-0. NPJ Breast Cancer. 2022. PMID: 36577758 Free PMC article. No abstract available.
Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy.
Gharbi SI, Pelletier LA, Espada A, Gutiérrez J, Sanfeliciano SMG, Rauch CT, Ganado MP, Baquero C, Zapatero E, Zhang A, Benach J, Russell AM, Cano L, Gomez S, Broughton H, Pulliam N, Perez CM, Torres R, Debets MF, de Dios A, Puig O, Hilgers MT, Lallena MJ. Gharbi SI, et al. Among authors: torres r. NPJ Breast Cancer. 2022 Nov 29;8(1):126. doi: 10.1038/s41523-022-00494-y. NPJ Breast Cancer. 2022. PMID: 36446794 Free PMC article.
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.
Gong X, Litchfield LM, Webster Y, Chio LC, Wong SS, Stewart TR, Dowless M, Dempsey J, Zeng Y, Torres R, Boehnke K, Mur C, Marugán C, Baquero C, Yu C, Bray SM, Wulur IH, Bi C, Chu S, Qian HR, Iversen PW, Merzoug FF, Ye XS, Reinhard C, De Dios A, Du J, Caldwell CW, Lallena MJ, Beckmann RP, Buchanan SG. Gong X, et al. Among authors: torres r. Cancer Cell. 2017 Dec 11;32(6):761-776.e6. doi: 10.1016/j.ccell.2017.11.006. Cancer Cell. 2017. PMID: 29232554 Free article.
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.
Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, Torres R, Ajamie RT, Wishart GN, Flack RS, Neubauer BL, Young J, Chan EM, Iversen P, Cronier D, Kreklau E, de Dios A. Gelbert LM, et al. Among authors: torres r. Invest New Drugs. 2014 Oct;32(5):825-37. doi: 10.1007/s10637-014-0120-7. Epub 2014 Jun 13. Invest New Drugs. 2014. PMID: 24919854 Free PMC article.
Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy.
Du J, Yan L, Torres R, Gong X, Bian H, Marugán C, Boehnke K, Baquero C, Hui YH, Chapman SC, Yang Y, Zeng Y, Bogner SM, Foreman RT, Capen A, Donoho GP, Van Horn RD, Barnard DS, Dempsey JA, Beckmann RP, Marshall MS, Chio LC, Qian Y, Webster YW, Aggarwal A, Chu S, Bhattachar S, Stancato LF, Dowless MS, Iversen PW, Manro JR, Walgren JL, Halstead BW, Dieter MZ, Martinez R, Bhagwat SV, Kreklau EL, Lallena MJ, Ye XS, Patel BKR, Reinhard C, Plowman GD, Barda DA, Henry JR, Buchanan SG, Campbell RM. Du J, et al. Among authors: torres r. Mol Cancer Ther. 2019 Dec;18(12):2207-2219. doi: 10.1158/1535-7163.MCT-18-0529. Epub 2019 Sep 17. Mol Cancer Ther. 2019. PMID: 31530649
Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks.
Suárez-García I, Alejos B, Moreno C, Martín Torres J, Masiá M, García-Fraile LJ, Riera M, Dalmau D, Rodríguez-Rosado R, Muga R, Moreno S, Jarrín I; CoRIS cohort. Suárez-García I, et al. J Antimicrob Chemother. 2024 Dec 23:dkae456. doi: 10.1093/jac/dkae456. Online ahead of print. J Antimicrob Chemother. 2024. PMID: 39710424
2024 Update of the RECOVER-Adult Long COVID Research Index.
Geng LN, Erlandson KM, Hornig M, Letts R, Selvaggi C, Ashktorab H, Atieh O, Bartram L, Brim H, Brosnahan SB, Brown J, Castro M, Charney A, Chen P, Deeks SG, Erdmann N, Flaherman VJ, Ghamloush MA, Goepfert P, Goldman JD, Han JE, Hess R, Hirshberg E, Hoover SE, Katz SD, Kelly JD, Klein JD, Krishnan JA, Lee-Iannotti J, Levitan EB, Marconi VC, Metz TD, Modes ME, Nikolich JŽ, Novak RM, Ofotokun I, Okumura MJ, Parthasarathy S, Patterson TF, Peluso MJ, Poppas A, Quintero Cardona O, Scott J, Shellito J, Sherif ZA, Singer NG, Taylor BS, Thaweethai T, Verduzco-Gutierrez M, Wisnivesky J, McComsey GA, Horwitz LI, Foulkes AS; RECOVER Consortium. Geng LN, et al. JAMA. 2024 Dec 18. doi: 10.1001/jama.2024.24184. Online ahead of print. JAMA. 2024. PMID: 39693079
2,004 results